Ivermectin Cannot Be Prescribed for Stage II Colorectal Cancer Under the Right to Try Act
Ivermectin is not an appropriate treatment option for stage II colorectal cancer and should not be prescribed for this indication, even under the Right to Try Act. The Right to Try Act specifically requires that investigational drugs have completed Phase I trials and be actively under FDA investigation for the specific condition being treated—criteria that ivermectin does not meet for colorectal cancer.
Why Ivermectin Is Not Appropriate
FDA-Approved Indications
Ivermectin is FDA-approved exclusively for parasitic infections (strongyloidiasis and onchocerciasis) 1. The drug label contains no oncology indications whatsoever, and there are no adequate and well-controlled studies in cancer patients.
Right to Try Act Requirements Not Met
The Right to Try Act requires:
- Active FDA investigation with an Investigational New Drug (IND) application
- Completion of Phase I safety trials for the specific indication
- Ongoing clinical development for that condition
Ivermectin has none of these for colorectal cancer. While preclinical studies show potential anticancer effects 2, 3, 4, there are no Phase I, II, or III clinical trials in humans with colorectal cancer, creating what experts describe as a "critical translational gap between preclinical results and practical clinical application" 5.
Evidence-Based Treatment for Stage II Colorectal Cancer
Standard of Care
According to the 2022 ASCO guidelines 6:
For most stage II colon cancer patients:
- Adjuvant chemotherapy should NOT routinely be offered (strong recommendation, moderate evidence quality) 6
- Surgery alone provides 68%-83% five-year disease-free survival 6
For high-risk stage II patients (T4 tumors, <12 lymph nodes sampled, perineural/lymphovascular invasion, poor differentiation, obstruction, perforation, high-grade tumor budding):
- Fluoropyrimidine-based adjuvant chemotherapy may be offered after shared decision-making 6
- Oxaliplatin addition is not routinely recommended but may be considered 6
Established Treatment Options
The NCCN guidelines 7 outline proven subsequent-line therapies for metastatic disease, including:
- Checkpoint inhibitors (pembrolizumab, nivolumab) for MMR-deficient tumors
- Targeted therapies (larotrectinib, entrectinib) for NTRK fusion-positive disease
- Regorafenib for refractory disease
None of these guidelines mention ivermectin as a treatment option.
Critical Safety and Ethical Concerns
Lack of Human Cancer Data
The most recent comprehensive review 5 from 2025 explicitly states: "Clinical evidence in humans is limited, with no large-scale randomized controlled trials (RCTs) confirming therapeutic benefits" for cancer treatment. The review warns that "observational studies and case reports highlight the risks of self-medication driven by social media touting Ivermectin's unproven cancer benefits, which can lead to toxicity in oncology patients."
Preclinical Evidence Is Insufficient
While laboratory studies show ivermectin can inhibit colorectal cancer cell growth through ROS-mediated apoptosis 2 and animal studies demonstrate some efficacy 3, preclinical data cannot substitute for human clinical trials. Even synergistic combinations with other agents 4 remain purely experimental.
Risk of Forgoing Proven Therapy
The most serious concern is that pursuing unproven treatments may lead patients to delay or refuse evidence-based interventions. For stage II colorectal cancer, this means potentially missing the window for curative surgery or appropriate adjuvant chemotherapy in high-risk cases.
Common Pitfalls to Avoid
- Confusing Right to Try with compassionate use: Right to Try has specific legal requirements that ivermectin does not meet for cancer
- Overinterpreting preclinical data: Laboratory and animal studies do not predict human efficacy or safety
- Social media misinformation: Patients may encounter unsubstantiated claims about ivermectin's cancer benefits 5
- Assuming "safe for parasites = safe for cancer": Dosing, duration, and drug interactions differ substantially between indications
Appropriate Clinical Response
Healthcare providers should:
- Clearly explain that ivermectin is not an evidence-based cancer treatment
- Discuss the proven treatment options outlined in ASCO guidelines 6
- For high-risk stage II patients, engage in shared decision-making about adjuvant chemotherapy
- Direct patients interested in investigational therapies toward legitimate clinical trials
- Document the discussion thoroughly to protect both patient and provider
The conversation should emphasize that while research into drug repurposing is valuable, patients deserve treatments with established efficacy and safety profiles for their specific cancer type and stage.